Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases
about
Phytochemicals and Biogenic Metallic Nanoparticles as Anticancer AgentsMatrix metalloproteinases: protective roles in cancer.Cardiovascular toxicity profiles of vascular-disrupting agents.The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models.Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapyOf dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma.Therapeutic modulation of prostate cancer metastasis.The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis.Miniaturized antibodies for imaging membrane type-1 matrix metalloproteinase in cancers.Upstream biomanufacturing of pharmaceutical colchicine.Antiangiogenesis enhances intratumoral drug retention.Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles.Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.A Novel Theranostic Strategy for MMP-14-Expressing Glioblastomas Impacts Survival.Optimization of a MT1-MMP-targeting Peptide and Its Application in Near-infrared Fluorescence Tumor Imaging.
P2860
Q26750806-B4A457A7-C520-4D49-9112-2AD239BF2D89Q35216059-69C2A3A7-8B5C-4476-8D4F-BCE7CF11EA34Q35584746-DE024FBF-6CC9-4402-8931-8756E834EFD4Q37153797-B679DFEC-1407-4114-9548-409071048647Q37624281-78A2DEA9-DF39-43BD-A4CC-A8F79C7B7B07Q37944599-7216A484-0DD9-4321-8F37-C2D59E5794DBQ38182140-B0D23CD6-36FB-4A7D-9CD8-B7B21401A2FDQ38192005-F6B0BDDB-852C-4B22-BB5B-11A51B261290Q38585273-54B7F837-CC8C-494E-88C9-3A5D203A714DQ39213090-3AA40E60-3136-4F6A-BF31-7CE435E11E93Q39235242-2D1674A1-DF9F-42F3-9C59-B6900E3968AAQ39568663-920F63F1-6699-48C6-A7EF-EADE8D494A01Q42364091-2974FF67-58CF-45EC-9413-71EEA534AAB4Q42632659-F0D0FF15-90F0-4D94-B318-5C796F42207CQ45966683-5E916006-1479-473E-B303-BD733828C416Q55546854-67596EC2-8BB3-4A6D-A133-F7EC8EFFB33E
P2860
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Development of a novel tumor-t ...... type matrix metalloproteinases
@ast
Development of a novel tumor-t ...... type matrix metalloproteinases
@en
Development of a novel tumor-t ...... type matrix metalloproteinases
@nl
type
label
Development of a novel tumor-t ...... type matrix metalloproteinases
@ast
Development of a novel tumor-t ...... type matrix metalloproteinases
@en
Development of a novel tumor-t ...... type matrix metalloproteinases
@nl
prefLabel
Development of a novel tumor-t ...... type matrix metalloproteinases
@ast
Development of a novel tumor-t ...... type matrix metalloproteinases
@en
Development of a novel tumor-t ...... type matrix metalloproteinases
@nl
P2093
P2860
P3181
P1433
P1476
Development of a novel tumor-t ...... type matrix metalloproteinases
@en
P2093
Caroline J Pennington
Catherine S Siller
Dylan R Edwards
Jason H Gill
Jennifer M Atkinson
Laurence H Patterson
Michael C Bibby
Paul M Loadman
Robert A Falconer
Steven D Shnyder
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-10-1440
P407
P577
2010-09-01T00:00:00Z